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Background
The mutation L76V is selected under lopinavir (LPV)-,
amprenavir (APV)- and darunavir (DRV)-containing regi-
mens with increasing prevalence. L76V decreases suscepti-
bility to LPV and APV, and increases susceptibility to SQV
and ATV. However, little is known about the clinical
implication of this mutation in the response to PI-con-
taining regimens in patients with strongly limited therapy
options.
Methods
Virological, immunological and genotypical data of 22
HIV-1 multiclass-resistant L76V-positive patients were
collected retrospectively. All patients were pre-treated for
a mean duration of 87 months, with a mean CD4 cell
count of 299 ± 221 cells/mL and a mean VL of 26,450 cop-
ies/mL. Thirteen patients switched to ATV or SQV plus
LPV or APV to maintain selection pressure on L76V and
nine patients received ATV and/or SQV only. Ten patients
had three-class resistant viruses, three had viruses with
resistance to NRTI and PI. Ten patients received an opti-
mized background therapy and another three received
double-PIs only. Viral load and CD4 counts were deter-
mined at baseline and week 12–96 to assess therapy suc-
cess (VL<50). Stanford HIVdb 4.2.6, REGA v7.0 and HIV-
GRADE 06–2007 were used for resistance predictions.
Phenotypic analyses in 10 patients were performed to ver-
ify the effects of resistance and resensitization.
Summary of results
Sustained therapy success was observed in 8/13 (61.5%)
patients, where selection pressure on L76V was constantly
maintained (one included new drug classes), while only
2/9 patients (22.2%) with ATV/SQV regimens only and
without selection pressure on L76V were successful (three
of them received supplemental new drug-classes). There
was a moderate increase of mean CD4 cell counts observ-
able in all patients with successful therapy follow-up.
Eight patients with failing treatment received a second
resistance test. While L76V was then undetectable in
patients without selection pressure, it persisted in patients
with LPV- or APV-containing regimens.
Conclusion
The co-existence of the L90M mutations was mostly
responsible for failure of therapy in these patients. L76V
was detected under LPV-, APV- and DRV-containing regi-
mens. ATV and/or SQV are encouraging options in deep
salvage-situations with viruses carrying the L76V muta-
tion. Maintenance of selection-pressure on L76V with APV
or LPV is beneficial for a sustained therapy success in ATV-
and/or SQV-containing regimens.
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